Boyds’ Chief Medical Officer Dr Karen Mullen has been awarded Fellowship of the Royal College of Physicians. The prestigious award recognises Karen’s standout contribution to medicine.
The Royal College of Physicians (RCP) is an independent patient centered and clinically led organisation that drives improvement in the diagnosis of disease, the care of individual patients and the health of the whole population, both in the UK and across the globe.
Fellows of the RCP are distinguished consultants or speciality and associate specialist doctors and are given the honour of using the FRCP (Fellowship of the Royal College of Physicians) postnominal. As an RCP fellow, Karen will belong to an influential and diverse community of changemakers aiming to shape better, more equitable healthcare.
A highly experienced pharmaceutical physician, Karen has worked internationally across a wide range of therapy areas, including respiratory, metabolic medicine, oncology, and immunology. She has been involved in the development and commercialisation of over 20 medicines including vaccines, diabetes treatments, gene therapy for ocular diseases, and monoclonal antibodies for a range of diseases. During her career, she has been involved in medical strategy and post surveillance monitoring for approximately 75 registered medicines.
Karen strongly believes in the UK being a centre for life sciences with world leading research in innovative therapies. She also supported a collaboration between NHS, academia, and industry as a member of the RCP Innovation in Health Group that enabled physicians to be involved in clinical trials to drive improvements in standards of care and patient outcomes.
Of receiving the fellowship, Karen said: “I am delighted and honoured to be awarded Fellowship of the Royal College of Physicians. I have always been passionate about fair access to innovative therapies and integrating them safely into clinical practice, and I will continue to work both at policy and R&D level to involve patients in the design and acceptability of clinical trials, ensuring all trials are representative of patient populations. I am looking forward to being part of the RCP’s dynamic community of fellows where I can influence positive change and help shape the future of healthcare.”
